Dipeptidyl peptidase-4 (DPP-4) inhibitors are promising medicines for treating type 2 diabetes mellitus (DM) and are expected to provide advantages over traditional DM treatments, including a low risk of hypoglycemia and weight gain [8]. This evidence concerns the gene DPP4 and Hypoglycemia.